Evidence map›Paper›PMID 12414507›Full record

ArticleThe American journal of pathology2002

Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.

Susanne V Allander, Peter B Illei, Yidong Chen, Cristina R Antonescu, Mike Bittner, Marc Ladanyi, Paul S Meltzer

Registry-linked trialOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01469975 (First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10), which is not on this map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01469975 phase1terminatednot on this mapstarted 2011, after this paper: background citation

First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas

TypeinterventionalSponsorCentre Leon BerardRan2011 to 2015Enrolled20ConditionsSarcoma, SynovialArmsOTSA101-DTPA-90Y level 1, OTSA101-DTPA-90Y level 2, OTSA101-DTPA-90Y level 3
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 185 citations in OpenAlex.

  1. Gene translocations in musculoskeletal neoplasms.Clinical orthopaedics and related research · 2008
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Observational
  6. An Overview of Advances in Rare Cancer Diagnosis and Treatment.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. The Impact of Microenvironment on the Synovial Sarcoma Transcriptome.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2017
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Susanne V AllanderCancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA. allands@war.wyeth.com
Peter B Illei
Yidong Chen
Cristina R Antonescu
Mike Bittner
Marc Ladanyi
Paul S Meltzer
Memorial Sloan Kettering Cancer Center · USNational Institutes of Health · USCancer Genetics (United States) · USNational Human Genome Research Institute · US

Funding

SOFT TISSUE SARCOMA PROGRAM PROJECTP01CA047179 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LADANYI, MARC · 1989 to 2010
$17.3M
Functional genomics of cancerZ01HG000186 · NHGRI · HUMAN GENOME RESEARCH · PI MELTZER, PAUL S. · 2001 to 2005
–
NCI NIH HHS P01 CA047179NCI NIH HHS P01 CA47179
6 · The paper itself

Abstract

Synovial sarcoma is an aggressive spindle cell sarcoma with two major histological subtypes, biphasic and monophasic, defined respectively by the presence or absence of areas of glandular epithelial differentiation. It is characterized by a specific chromosomal translocation, t(X;18)(p11.2;q11.2), which juxtaposes the SYT gene on chromosome 18 to either the SSX1 or the SSX2 gene on chromosome X. The chimeric SYT-SSX products are thought to function as transcriptional proteins that deregulate gene expression, thereby providing a putative oncogenic stimulus. We investigated the pattern of gene expression in synovial sarcoma using cDNA microarrays containing 6548 sequence-verified human cDNAs. A tissue microarray containing 37 synovial sarcoma samples verified to bear the SYT-SSX fusion was constructed for complementary analyses. Gene expression analyses were performed on individual tumor samples; 14 synovial sarcomas, 4 malignant fibrous histiocytomas, and 1 fibrosarcoma. Statistical analysis showed a distinct expression profile for the group of synovial sarcomas as compared to the other soft tissue sarcomas, which included variably high expression of ERBB2, IGFBP2, and IGF2 in the synovial sarcomas. Immunohistochemical analysis of protein expression in tissue microarrays of 37 synovial sarcomas demonstrated strong expression of ERBB2 and IGFBP2 in the glandular epithelial component of biphasic tumors and in solid epithelioid areas of some monophasic tumors. Fluorescence in situ hybridization analysis indicated that the ERBB2 overexpression was not because of gene amplification. Differentially expressed genes were also found in a comparison of the expression profiles of the biphasic and monophasic histological subgroups of synovial sarcoma, notably several keratin genes, and ELF3, an epithelial-specific transcription factor gene. Finally, we also noted differential overexpression of several neural- or neuroectodermal-associated genes in synovial sarcomas relative to the comparison sarcoma group, including OLFM1, TLE2, CNTNAP1, and DRPLA. Our high-throughput studies of gene expression patterns, complemented by tissue microarray studies, confirm the distinctive expression profile of synovial sarcoma, provide leads for the study of glandular morphogenesis in this tumor, and identify a new potential therapeutic target, ERBB2, in a subset of cases.

Indexed as

DNA-Binding ProteinsCell DifferentiationEpithelial CellsErb-b2 Receptor Tyrosine KinasesGene Expression ProfilingHumansImmunohistochemistryIn Situ Hybridization, FluorescenceInsulin-Like Growth Factor Binding Protein 2Oligonucleotide Array Sequence AnalysisProto-Oncogene ProteinsProto-Oncogene Proteins c-etsRNA, NeoplasmSarcoma, SynovialTranscription FactorsTumor Cells, CulturedDNA-Binding ProteinsELF3 protein, humanErb-b2 Receptor Tyrosine KinasesInsulin-Like Growth Factor Binding Protein 2Proto-Oncogene ProteinsProto-Oncogene Proteins c-etsRNA, NeoplasmTranscription Factors

Identifiers

PMID12414507
PMCPMC1850795
OpenAlexW1208928033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.